Piers Blombery

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

Rachel Thijssen, Luyi Tian, Mary Ann Anderson, Christoffer Flensburg, Andrew Jarratt, Alexandra L Garnham, Jafar S Jabbari, Hongke Peng, Thomas E Lew, Charis E Teh, Quentin Gouil, Angela Georgiou, Tania Tan, Tirta M Djajawi, Constantine S Tam, John F Seymour, Piers Blombery, Daniel HD Gray, Ian J Majewski, Matthew E Ritchie, et al.

Journal article  |  2022  |  BLOOD

Venetoclax (VEN) inhibits the prosurvival protein BCL2 to induce apoptosis and is a standard therapy for chronic lymphocytic leuke..

ALLSorts: an RNA-Seq subtype classifier for B-cell acute lymphoblastic leukemia

Breon Schmidt, Lauren M Brown, Georgina L Ryland, Andrew Lonsdale, Hansen J Kosasih, Louise E Ludlow, Ian J Majewski, Piers Blombery, Paul G Ekert, Nadia M Davidson, Alicia Oshlack

Journal article  |  2022  |  BLOOD ADVANCES

B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer. Subtypes within B-ALL are distinguished by charac..

Methyl-CpG binding domain 4, DNA glycosylase (MBD4)-associated neoplasia syndrome associated with a homozygous missense variant in MBD4: Expansion of an emerging phenotype

Piers Blombery, Georgina L Ryland, Lucy C Fox, Zornitza Stark, Meg Wall, Anna Jarmolowicz, Ain Roesley, Ella R Thompson, Sean M Grimmond, Shyam Panicker, Fiona Kwok

Journal article  |  2022  |  BRITISH JOURNAL OF HAEMATOLOGY

Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre

Constantine S Tam, Gareth P Gregory, Matthew Ku, Shaun Fleming, Sasanka M Handunnetti, Denise Lee, Patricia Walker, Andrew Perkins, Thomas E Lew, Shreerang Sirdesai, Chong Chyn Chua, Michael Gilbertson, Masa Lasica, Mary Ann Anderson, William Renwick, Andrew Grigg, Sush Patil, Stephen Opat, Adam Friebe, Rachel Cooke, et al.

Journal article  |  2022  |  INTERNAL MEDICINE JOURNAL

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia

Shunsuke Kimura, Lindsey Montefiori, Ilaria Iacobucci, Yaqi Zhao, Qingsong Gao, Elisabeth M Paietta, Claudia Haferlach, A Douglas Laird, Paul E Mead, Zhaohui Gu, Wendy Stock, Mark Litzow, Jacob M Rowe, Selina M Luger, Stephen P Hunger, Georgina L Ryland, Breon Schmidt, Paul G Ekert, Alicia Oshlack, Sean M Grimmond, et al.

Journal article  |  2022  |  BLOOD

Transcriptome sequencing has identified multiple subtypes of B-progenitor acute lymphoblastic leukemia (B-ALL) of prognostic signi..

Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement

Anoop K Enjeti, Rishu Agarwal, Piers Blombery, Lynette Chee, Chong Chyn Chua, Andrew Grigg, Nada Hamad, Harry Iland, Steven Lane, Andrew Perkins, Deepak Singhal, Courtney Tate, Ing Soo Tiong, David M Ross

Journal article  |  2022  |  PATHOLOGY

This review aims to provide an expert consensus statement to address the role of gene-panel testing in the diagnosis, prognosis an..

Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnostics

Kenneth D Doig, Christopher G Love, Thomas Conway, Andrei Seleznev, David Ma, Andrew Fellowes, Piers Blombery, Stephen B Fox

Journal article  |  2022  |  BMC MEDICAL GENOMICS

BACKGROUND: Next generation sequencing for oncology patient management is now routine in clinical pathology laboratories. Although..

Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review

Martin Vu, Koen Degeling, Ella R Thompson, Piers Blombery, David Westerman, Maarten J IJzerman

Journal article  |  2022  |  EUROPEAN JOURNAL OF HAEMATOLOGY

OBJECTIVES: Molecular biomarker tests can inform the clinical management of genomic heterogeneous hematological malignancies, yet ..

Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL

Piers Blombery, Thomas E Lew, Michael A Dengler, Ella R Thompson, Victor S Lin, Xiangting Chen, Tamia Nguyen, Ashish Panigrahi, Sasanka M Handunnetti, Dennis A Carney, David A Westerman, Constantine S Tam, Jerry M Adams, Andrew H Wei, David CS Huang, John F Seymour, Andrew W Roberts, Mary Ann Anderson

Journal article  |  2022  |  BLOOD

The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (..

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors

Ella R Thompson, Tamia Nguyen, Yamuna Kankanige, John F Markham, Mary Ann Anderson, Sasanka M Handunnetti, Rachel Thijssen, Paul Sung-Hao Yeh, Constantine S Tam, John F Seymour, Andrew W Roberts, David A Westerman, Piers Blombery

Journal article  |  2022  |  BLOOD ADVANCES

The genomic landscape of resistance to targeted agents (TAs) used as monotherapy in chronic lymphocytic leukemia (CLL) is complex ..